Design and Computational Analysis of an MMP9 Inhibitor in Hypoxia-Induced Glioblastoma Multiforme

Area of Science:

• Biochemistry
• Oncology
• Pharmacology

Background:

• Hypoxia-induced glioblastoma multiforme (GBM) presents therapeutic challenges due to treatment toxicity and microenvironmental resistance.
• Novel therapeutic strategies are crucial to reduce GBM lethality and overcome drug resistance.

Purpose of the Study:

• To identify novel plant-based natural products as potential therapeutic agents for hypoxia-induced GBM.
• To discover new drug candidates that circumvent existing resistance mechanisms and possess favorable pharmacokinetic properties.

Main Methods:

• Differential gene expression analysis of hypoxia-specific genes in GBM using GEO data.
• Construction of a protein-protein interaction (PPI) network to identify hub genes.
• Validation of hub genes in GBM patient samples using multiple bioinformatics tools (GEPIA2.0, TIMER2.0, TCGA-GBM, GlioVis).
• In silico analysis including molecular docking, MD simulation, and ADMET prediction for drug-likeness and blood-brain barrier penetration.

Main Results:

• Identified 2429 hypoxia-specific differentially expressed genes in GBM.
• Discovered 32 hub genes, with LYN, MMP9, PSMB9, and TIMP1 highlighted as GBM-specific hypoxic genes linked to the tumor microenvironment.
• Screened 11 plant-derived compounds exhibiting good drug-likeness, non-toxicity, and blood-brain barrier permeability.
• Identified specific flavonoids (e.g., 7,4'-dihydroxyflavan) that inhibit MMP9 through molecular docking and simulation studies.

Conclusions:

• MMP9 is a novel hypoxia gene signature and a potential therapeutic target in GBM.
• Identified flavonoids demonstrate potential as novel, non-toxic therapeutic agents for GBM, offering a promising avenue for targeted therapy.
• These findings could lead to improved diagnostic and prognostic tools for GBM patients.